Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
October 17, 2025 16:05 ET | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period…
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
MOORESVILLE, N.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, a trusted leader in premium dispensary-grade hemp-derived products, has…
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for…
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025…
MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it…
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a…